Trial Profile
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms MONARCH 1
- Sponsors Eli Lilly and Company
- 05 Dec 2023 Results presented in an Eli Lilly and Company Media Release.
- 01 Jul 2021 Results of post hoc pooled analysis (n=1284) assessing the prognostic association between pretreatment patient-reported outcomes and progression-free survival, the prediction performance of PROs compared with ECOG-PS and the effect of PROs on the treatment benefit of abemaciclib versus comparator therapy from MONARCH 1, MONARCH 2 and MONARCH 3 studies, assessing published in the Oncologist.
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.